193 related articles for article (PubMed ID: 32727965)
1. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment.
Yi W; Kim BH; Kim M; Ryang SR; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
Endocr J; 2020 Dec; 67(12):1193-1198. PubMed ID: 32727965
[TBL] [Abstract][Full Text] [Related]
2. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.
Molinaro E; Leboeuf R; Shue B; Martorella AJ; Fleisher M; Larson S; Tuttle RM
Thyroid; 2009 Oct; 19(10):1035-41. PubMed ID: 19772430
[TBL] [Abstract][Full Text] [Related]
3. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.
Hu T; Meng Z; Zhang G; Jia Q; Tan J; Zheng W; Wang R; Li X; Liu N; Zhou P; Upadhyaya A
Medicine (Baltimore); 2016 Aug; 95(35):e4451. PubMed ID: 27583853
[TBL] [Abstract][Full Text] [Related]
4. Bone-Marrow Suppression in Elderly Patients Following Empiric Radioiodine Therapy: Real-Life Data.
Duskin-Bitan H; Leibner A; Amitai O; Diker-Cohen T; Hirsch D; Benbassat C; Shimon I; Robenshtok E
Thyroid; 2019 May; 29(5):683-691. PubMed ID: 31084551
[No Abstract] [Full Text] [Related]
5. Comparison between the different doses of radioactive iodine ablation prescribed in patients with intermediate-to-high-risk differentiated thyroid cancer.
Iizuka Y; Katagiri T; Ogura K; Mizowaki T
Ann Nucl Med; 2019 Jul; 33(7):495-501. PubMed ID: 30955202
[TBL] [Abstract][Full Text] [Related]
6. Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer.
Padovani RP; Tuttle RM; Grewal R; Larson SM; Boucai L
Endocr Pract; 2014 Mar; 20(3):213-20. PubMed ID: 24126230
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy.
Dong P; Wang L; Huang R; Li L
Medicine (Baltimore); 2020 Jul; 99(31):e21398. PubMed ID: 32756134
[TBL] [Abstract][Full Text] [Related]
8. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
9. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
10. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system.
Zeuren R; Biagini A; Grewal RK; Randolph GW; Kamani D; Sabra MM; Shaha AR; Tuttle RM
Laryngoscope; 2015 Oct; 125(10):2417-24. PubMed ID: 25891354
[TBL] [Abstract][Full Text] [Related]
11. Transient Leukopenia After Radioactive Iodine Treatment in Patients With Graves' Disease: A Retrospective Cohort Study.
Yamashita K; Morimoto S; Kimura S; Seki Y; Bokuda K; Watanabe D; Yazaki T; Abe K; Ichihara A
J Endocr Soc; 2021 May; 5(5):bvab039. PubMed ID: 33928204
[TBL] [Abstract][Full Text] [Related]
12. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
[No Abstract] [Full Text] [Related]
13. Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial.
Marina M; Maglietta G; De Filpo G; Aloe R; Gnocchi C; Iezzi E; Caminiti C; Ceresini G
Endocrine; 2022 Aug; 77(2):340-348. PubMed ID: 35751777
[TBL] [Abstract][Full Text] [Related]
14. Decreasing Use of Radioactive Iodine for Low-Risk Thyroid Cancer in California, 1999 to 2015.
Park KW; Wu JX; Du L; Leung AM; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2018 Mar; 103(3):1095-1101. PubMed ID: 29267880
[TBL] [Abstract][Full Text] [Related]
15. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
16. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer.
Stevic I; Dembinski TC; Pathak KA; Leslie WD
Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485
[TBL] [Abstract][Full Text] [Related]
17. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review.
Blumhardt R; Wolin EA; Phillips WT; Salman UA; Walker RC; Stack BC; Metter D
Endocr Relat Cancer; 2014; 21(6):R473-84. PubMed ID: 25277792
[TBL] [Abstract][Full Text] [Related]
18. The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer.
Demir AN; Kara Z; Sulu C; Uysal S; Zulfaliyeva G; Atar OA; Valikhanova N; Ozturk T; Ozkaya HM; Damci T; Gonen MS
Hormones (Athens); 2023 Dec; 22(4):595-602. PubMed ID: 37603221
[TBL] [Abstract][Full Text] [Related]
19. Is radioactive iodine- 131 treatment related to the occurrence of non-synchronous second primary malignancy in patients with differentiated thyroid cancer?
Souza MC; Momesso DP; Vaisman F; Vieira Neto L; Martins RA; Corbo R; Vaisman M
Arch Endocrinol Metab; 2016 Feb; 60(1):9-15. PubMed ID: 26222230
[TBL] [Abstract][Full Text] [Related]
20. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.
Momesso DP; Vaisman F; Caminha LS; Pessoa CH; Corbo R; Vaisman M
J Endocrinol Invest; 2014 Jan; 37(1):57-64. PubMed ID: 24464451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]